Car T-Cell Therapy

Crystal L. Mackall, MD, believes she has an "unusual pedigree" for someone in her position.

The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.

CHICAGO — Second-line therapy with lisocabtagene maraleucel induced initial complete remission among more than half of patients with relapsed or refractory transplant-ineligible large B-cell lymphoma, results from a phase 2 trial showed.

CHICAGO — A single dose of an investigational chimeric antigen receptor T-cell therapy induced an objective response in nearly 90% of patients with relapsed or refractory multiple myeloma, phase 1 study results showed.

The FDA granted regenerative medicine advanced therapy designation to ALLO-501, a chimeric antigen receptor T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma.

CHICAGO — A novel chimeric antigen receptor T-cell therapy has elicited objective responses among the first 10 patients who received the treatment, according to results from the phase 1 POLARIS trial presented at ASCO Annual Meeting.

CHICAGO — A single dose of a novel chimeric antigen receptor T-cell therapy induced objective response among all treated patients with relapsed or refractory multiple myeloma, according to study results presented at ASCO Annual Meeting.

CHICAGO — Axicabtagene ciloleucel exhibited comparable efficacy and safety for large B-cell lymphoma regardless of patients’ race or ethnicity, according to study results presented at ASCO Annual Meeting.

In this video, Yael Malul, MSN, RN, AGACNP-BC, OCN, discussed presentations on immune effector cell administration best practices and new treatment strategies for multiple myeloma at Oncology Nursing Society Congress 2022.

Multiple myeloma is the most common indication for autologous stem cell transplantation worldwide.